Overview
Seattle Cancer Care Alliance (SCCA) provides comprehensive, leading-edge treatment for people diagnosed with multiple myeloma, a form of cancer that affects white blood cells called plasma cells.
SCCA was formed, in part, to bring promising new cancer treatments to patients faster. This means that people who have myeloma will find more treatment options at SCCA than might be found elsewhere. Many or our patients receive such therapies through clinical research studies conducted at SCCA and its parent organizations, Fred Hutchinson Cancer Research Center and UW Medicine. The physicians and scientists here are world leaders in research to better understand the causes of myeloma and provide effective treatments.
Stem cell transplants (using peripheral blood stem cells or stem cells from bone marrow) are an important treatment option for people with myeloma who are good candidates for transplant. The Fred Hutchinson Transplant program at SCCA ranked first in outcomes in a five-year study by the National Marrow Donor Program that measured one-year survival rates of patients among 122 transplant centers in the United States.
For all our patients with myeloma, we offer numerous combinations of treatment options—including chemotherapy, radiation, and other therapies for disease-related complications—based on each person’s unique situation.

